PGEN vs. BLTE, IDYA, HRMY, IRON, CNTA, APGE, ADPT, SRPT, SPRY, and TARS
Should you be buying Precigen stock or one of its competitors? The main competitors of Precigen include Belite Bio (BLTE), IDEAYA Biosciences (IDYA), Harmony Biosciences (HRMY), Disc Medicine (IRON), Centessa Pharmaceuticals (CNTA), Apogee Therapeutics (APGE), Adaptive Biotechnologies (ADPT), Sarepta Therapeutics (SRPT), ARS Pharmaceuticals (SPRY), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry.
Precigen vs. Its Competitors
Belite Bio (NASDAQ:BLTE) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.
Belite Bio has higher earnings, but lower revenue than Precigen. Belite Bio is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Belite Bio had 2 more articles in the media than Precigen. MarketBeat recorded 10 mentions for Belite Bio and 8 mentions for Precigen. Precigen's average media sentiment score of 1.10 beat Belite Bio's score of 0.52 indicating that Precigen is being referred to more favorably in the news media.
Belite Bio has a beta of -1.5, meaning that its share price is 250% less volatile than the S&P 500. Comparatively, Precigen has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500.
0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 47.1% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Belite Bio has a net margin of 0.00% compared to Precigen's net margin of -3,728.87%. Belite Bio's return on equity of -32.07% beat Precigen's return on equity.
Belite Bio currently has a consensus price target of $96.67, indicating a potential upside of 55.79%. Precigen has a consensus price target of $6.00, indicating a potential upside of 226.09%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than Belite Bio.
Summary
Precigen beats Belite Bio on 8 of the 14 factors compared between the two stocks.
Get Precigen News Delivered to You Automatically
Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Precigen Competitors List
Related Companies and Tools
This page (NASDAQ:PGEN) was last updated on 7/17/2025 by MarketBeat.com Staff
Free PGEN Stock Alerts